Post-transplant infections: An ounce of prevention

Indian Journal of Nephrology

Volumn 20, Issue 4, 2010, Pages 171-178

  Jha, V ^a  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

Infections; kidney transplantation; prevention

Indexed keywords

ACICLOVIR; ADEFOVIR; ANTIVIRUS AGENT; CLOTRIMAZOLE; COTRIMOXAZOLE; ENTECAVIR; GANCICLOVIR; HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NYSTATIN; TACROLIMUS; VACCINE; VALGANCICLOVIR;

ANTIBODY RESPONSE; ANTIBODY TITER; BACTEREMIA; BACTERIAL INFECTION; BK VIRUS; CANDIDIASIS; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CLINICAL ASSESSMENT; COMPUTER ASSISTED TOMOGRAPHY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DIABETES MELLITUS; DISEASE COURSE; DISEASE TRANSMISSION; DRUG COST; DRUG EFFICACY; EPSTEIN BARR VIRUS; GRAFT RECIPIENT; HEPATITIS B; HEPATITIS B VIRUS; HOSPITALIZATION; HUMAN; IMMUNOASSAY; INFECTION RISK; KIDNEY DISEASE; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LIVER DISEASE; LYMPHOPROLIFERATIVE DISEASE; NOCARDIOSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PNEUMOCYSTIS; POSTOPERATIVE INFECTION; PYELONEPHRITIS; REVIEW; SEROLOGY; SYSTEMIC LUPUS ERYTHEMATOSUS; URINARY TRACT INFECTION; VACCINATION; VIRUS INFECTION; VIRUS REACTIVATION;

EID: 78650148648     PISSN: 09714065     EISSN: 19983662     Source Type: Journal    
DOI: 10.4103/0971-4065.73431     Document Type: Review

References (55)

1. Snyder JJ, Israni AK, Peng Y, Zhang L, Simon TA, Kasiske BL, et al. Rates of first infection following kidney transplant in the United States. Kidney Int 2009;75:317-26.
2. US Renal Data System: Annual Data Report 2008. Available from: http://www.usrds.org/adr. [Last accessed on 2008 Dec 15].
3. Dharnidharka VR, Stablein DM, Harmon WE. Post-transplant infections now exceed acute rejection as cause for hospitalization: A report of the NAPRTCS. Am J Transplant 2004;4:384-9.
4. Dharnidharka VR, Agodoa LY, Abbott KC. Risk factors for hospitalization for bacterial or viral infection in renal transplant recipients-an analysis of USRDS data. Am J Transplant 2007;7:653-61.
5. Fishman JA. Infection in renal transplant recipients. Semin Nephrol 2007;27:445-61.
6. Kotton CN, Fishman JA. Viral infection in the renal transplant recipient. J Am Soc Nephrol 2005;16:1758-74.
7. Schaub S, Wilkins JA, Rush D, Nickerson P. Developing a tool for noninvasive monitoring of renal allografts. Expert Rev Proteomics 2006;3:497-509.
8. Kowalski RJ, Post DR, Mannon RB, Sebastian A, Wright HI, Sigle G, et al. Assessing relative risks of infection and rejection: A meta-analysis using an immune function assay. Transplantation 2006;82:663-8.
9. Batal I, Zeevi A, Heider A, Girnita A, Basu A, Tan H, et al. Measurements of global cell-mediated immunity in renal transplant recipients with BK virus reactivation. Am J Clin Pathol 2008;129:587-91.
10. Gautam A, Morrissey PE, Brem AS, Fischer SA, Gohh RY, Yango AF, et al. Use of an immune function assay to monitor immunosuppression for treatment of post-transplant lymphoproliferative disorder. Pediatr Transplant 2006;10:613-6.
11. Nikaein A, Spiridon C, Hunt J, Rosenthal J, Anderson A, Eichhorn E, et al. Pre-transplant level of soluble CD30 is associated with infection after heart transplantation. Clin Transplant 2007;21:744-7.
12. Li L, Chaudhuri A, Weintraub LA, Hsieh F, Shah S, Alexander S, et al. Subclinical cytomegalovirus and Epstein-Barr virus viremia are associated with adverse outcomes in pediatric renal transplantation. Pediatr Transplant 2007;11:187-95.
13. Franco A, Serrano R, Gimeno A, de Juan J, Merino E, Jimnez del Cerro L, et al. Evaluation of viral load and antigenemia as markers for relapse cytomegalovirus infection in renal transplant recipients. Nefrologia 2007;27:202-8.
14. Schaffner A. Pretransplant evaluation for infections in donors and recipients of solid organs. Clin Infect Dis 2001;33:S9-14.
15. Veroux P, Veroux M, Puliatti C, Cappello D, Macarone M, Gagliano M, et al. Kidney transplantation from hepatitis C virus-positive donors into hepatitis C virus-positive recipients: A safe way to expand the donor pool? Transplant Proc 2005;37:2571-3.
16. Abbott KC, Lentine KL, Bucci JR, Agodoa LY, Peters TG, Schnitzler MA. The impact of transplantation with deceased donor hepatitis c-positive kidneys on survival in wait-listed long-term dialysis patients. Am J Transplant 2004;4:2032-7.
17. Veroux M, Puliatti C, Gagliano M, Cappello D, Macarone M, Vizcarra D, et al. Use of hepatitis B core antibody-positive donor kidneys in hepatitis B surface antibody-positive and-negative recipients. Transplant Proc 2005;37:2574-5.
18. Madayag RM, Johnson LB, Bartlett ST, Schweitzer EJ, Constantine NT, McCarter RJ Jr, et al. Use of renal allografts from donors positive for hepatitis B core antibody confers minimal risk for subsequent development of clinical hepatitis B virus disease. Transplantation 1997;64:1781-6.
19. Neuhaus TJ. Immunization in children with chronic renal failure: A practical approach. Pediatr Nephrol 2004;19:1334-9.
20. Rand EB, McCarthy CA, Whitington PF. Measles vaccination after orthotopic liver transplantation. J Pediatr 1993;123:87-9.
21. Zamora I, Simon JM, Da Silva ME, Piqueras AI. Attenuated varicella virus vaccine in children with renal transplants. Pediatr Nephrol 1994;8:190-2.
22. Guidelines for vaccination of solid organ transplant candidates and recipients. Am J Transplant 2004;4:160-3.
23. Furth SL, Fivush BA. Varicella vaccination in pediatric kidney transplant candidates. Pediatr Transplant 2002;6:97-100.
24. Olson AD, Shope TC, Flynn JT. Pretransplant varicella vaccination is cost-effective in pediatric renal transplantation. Pediatr Transplant 2001;5:44-50.
25. de Souza RM, Olsburgh J. Urinary tract infection in the renal transplant patient. Nat Clin Pract Nephrol 2008;4:252-64.
26. Senger SS, Arslan H, Azap OK, Timurkaynak F, Cair U, Haberal M. Urinary tract infections in renal transplant recipients. Transplant Proc 2007;39:1016-7.
27. Hodson EM, Barclay PG, Craig JC, Jones C, Kable K, Strippoli GF, et al. Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients. Cochrane Database Syst Rev 2005;19:CD003774.
28. Kalil AC, Levitsky J, Lyden E, Stoner J, Freifeld AG. Meta-analysis: The efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients. Ann Intern Med 2005;143:870-80.
29. Asberg A, Humar A, Rollag H, Jardine AG, Mouas H, Pescovitz MD, et al. Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2007;7:2106-13.
30. Avidan YP, Paul M, Rahamimov R, Bishara J, Samra Z, Edna S, et al. Selective low-dose valganciclovir for prevention of cytomegalovirus disease following kidney transplantation. J Infect 2008;57:236-40.
31. Weng FL, Patel AM, Wanchoo R, Brahmbhatt Y, Ribeiro K, Uknis ME, et al. Oral ganciclovir versus low-dose valganciclovir for prevention of cytomegalovirus disease in recipients of kidney and pancreas transplants. Transplantation 2007;83:290-6.
32. Taber DJ, Ashcraft E, Baillie GM, Berkman S, Rogers J, Baliga PK, et al. Valganciclovir prophylaxis in patients at high risk for the development of cytomegalovirus disease. Transpl Infect Dis 2004;6:101-9.
33. Arthurs SK, Eid AJ, Pedersen RA, Kremers WK, Cosio FG, Patel R, et al. Delayed-onset primary cytomegalovirus disease and the risk of allograft failure and mortality after kidney transplantation. Clin Infect Dis 2008;46:840-6.
34. Limaye AP, Bakthavatsalam R, Kim HW, Randolph SE, Halldorson JB, Healey PJ, et al. Impact of cytomegalovirus in organ transplant recipients in the era of antiviral prophylaxis. Transplantation 2006;81:1645-52.
35. Eid AJ, Arthurs SK, Deziel PJ, Wilhelm MP, Razonable RR. Emergence of drug-resistant cytomegalovirus in the era of valganciclovir prophylaxis: Therapeutic implications and outcomes. Clin Transplant 2008;22:162-70.
36. Strippoli GF, Hodson EM, Jones CJ, Craig JC. Pre-emptive treatment for cytomegalovirus viraemia to prevent cytomegalovirus disease in solid organ transplant recipients. Cochrane Database Syst Rev 2006;1:CD005133.
37. Khoury JA, Storch GA, Bohl DL, Schuessler RM, Torrence SM, Lockwood M, et al. Prophylactic versus preemptive oral valganciclovir for the management of cytomegalovirus infection in adult renal transplant recipients. Am J Transplant 2006;6:2134-43.
38. Kliem V, Fricke L, Wollbrink T, Burg M, Radermacher J, Rohde F. Improvement in long-term renal graft survival due to CMV prophylaxis with oral ganciclovir: Results of a randomized clinical trial. Am J Transplant 2008;8:975-83.
39. Conti DJ, Freed BM, Singh TP, Gallichio M, Gruber SA, Lempert N. Preemptive ganciclovir therapy in cytomegalovirus-seropositive renal transplants recipients. Arch Surg 1995;130:1217-21.
40. Hibberd PL, Tolkoff-Rubin NE, Conti D, Stuart F, Thistlethwaite JR, Neylan JF, et al. Preemptive ganciclovir therapy to prevent cytomegalovirus disease in cytomegalovirus antibody-positive renal transplant recipients. A randomized controlled trial. Ann Intern Med 1995;123:18-26.
41. Funch DP, Walker AM, Schneider G, Ziyadeh NJ, Pescovitz MD. Ganciclovir and acyclovir reduce the risk of post-transplant lymphoproliferative disorder in renal transplant recipients. Am J Transplant 2005;5:2894-900.
42. Opelz G, Daniel V, Naujokat C, Fickenscher H, Dhler B. Effect of cytomegalovirus prophylaxis with immunoglobulin or with antiviral drugs on post-transplant non-Hodgkin lymphoma: A multicentre retrospective analysis. Lancet Oncol 2007;8:212-8.
43. Fabrizi F, Martin P, Dixit V, Kanwal F, Dulai G. HBsAg seropositive status and survival after renal transplantation: Meta-analysis of observational studies. Am J Transplant 2005;5:2913-21.
44. Fabrizi F, Dulai G, Dixit V, Bunnapradist S, Martin P. Lamivudine for the treatment of hepatitis B virus-related liver disease after renal transplantation: Meta-analysis of clinical trials. Transplantation 2004;77:859-64.
45. Filik L, Karakayali H, Moray G, Dalgi A, Emirolu R, Ozdemir N, et al. Lamivudine therapy in kidney allograft recipients who are seropositive for hepatitis B surface antigen. Transplant Proc 2006;38:496-8.
46. Fontaine H, Vallet-Pichard A, Chaix ML, Currie G, Serpaggi J, Verkarre V, et al. Efficacy and safety of adefovir dipivoxil in kidney recipients, hemodialysis patients, and patients with renal insufficiency. Transplantation 2005;80:1086-92.
47. Kamar N, Milioto O, Alric L, El Kahwaji L, Cointault O, Lavayssire L, et al. Entecavir therapy for adefovir-resistant hepatitis B virus infection in kidney and liver allograft recipients. Transplantation 2008;86:611-4.
48. Pang XL, Doucette K, LeBlanc B, Cockfield SM, Preiksaitis JK. Monitoring of polyomavirus BK virus viruria and viremia in renal allograft recipients by use of a quantitative real-time PCR assay: One-year prospective study. J Clin Microbiol 2007;45:3568-73.
49. Mischitelli M, Bellizzi A, Anzivino E, Fioriti D, Boldorini R, Miglio U, et al. Complications post renal transplantation: Literature focus on BK virus nephropathy and diagnostic tools actually available. Virol J 2008;5:38.
50. Drachenberg CB, Papadimitriou JC, Hirsch HH, Wali R, Crowder C, Nogueira J, et al. Histological patterns of polyomavirus nephropathy: Correlation with graft outcome and viral load. Am J Transplant 2004;4:2082-92.
51. Hirsch HH, Brennan DC, Drachenberg CB, Ginevri F, Gordon J, Limaye AP, et al. Polyomavirus-associated nephropathy in renal transplantation: Interdisciplinary analyses and recommendations. Transplantation 2005;79:1277-86.
52. Randhawa P, Ho A, Shapiro R, Vats A, Swalsky P, Finkelstein S, et al. Correlates of quantitative measurement of BK polyomavirus (BKV) DNA with clinical course of BKV infection in renal transplant patients. J Clin Microbiol 2004;42:1176-80.
53. Drachenberg CB, Papadimitriou JC, Ramos E. Histologic versus molecular diagnosis of BK polyomavirus-associated nephropathy: A shifting paradigm? Clin J Am Soc Nephrol 2006;1:374-9.
54. Smith JM, McDonald RA. Emerging viral infections in transplantation. Pediatr Transplant 2006;10:838-43.
55. Fischer SA. Emerging viruses in transplantation: There is more to infection after transplant than CMV and EBV. Transplantation 2008;86:1327-39.